EditorialEditorial
Open Access

Tumor microenvironment-responsive polymeric nanoparticles for enhanced immunotherapy

Yongxin Zhang, Shaobing Zhou and Jingya Zhao
Cancer Biology & Medicine December 2025, 20250517; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0517

References

  1. 1.↵
    2. Bray F,
    3. Laversanne M,
    4. Sung H,
    5. Ferlay J,
    6. Siegel RL,
    7. Soerjomataram I, et al.
    Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229–63.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Mellman I,
    3. Chen DS,
    4. Powles T,
    5. Turley SJ.
    The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023; 56: 2188–205.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Sun D-Y,
    3. Hu Y-J,
    4. Li X,
    5. Peng J,
    6. Dai Z-J,
    7. Wang S.
    Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies. Int Immunopharmacol. 2025; 144: 113392.
  4. 4.↵
    2. Zhang J,
    3. Huang D,
    4. Saw PE,
    5. Song E.
    Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol. 2022; 43: 523–45.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Vargason  AM,
    3. Anselmo AC ,
    4. Mitragotri S.
    The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021; 5: 951–67.
    OpenUrlPubMed
  6. 6.↵
    2. De Visser KE,
    3. Joyce JA.
    The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023; 41: 374–403.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Zhang Y,
    3. Zhang Z.
    The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020; 17: 807–21.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Gao Y,
    3. Wang Y,
    4. Jiang J,
    5. Wei P,
    6. Sun H.
    Triggered “on/off” luminescent polypeptide bowl-shaped nanoparticles for selective lighting of tumor cells. Small. 2025; 11: 2411432.
  9. 9.↵
    2. Wei D,
    3. Sun Y,
    4. Zhu H,
    5. Fu Q.
    Stimuli-responsive polymer-based nanosystems for cancer theranostics. ACS Nano. 2023; 17: 23223–61.
    OpenUrlPubMed
  10. 10.↵
    2. Zhang Y,
    3. Ma F,
    4. Chen J,
    5. Chen Y,
    6. Xu L,
    7. Li A, et al.
    Controlled refolding of denatured IL-12 Using in situ antigen-capturing nanochaperone remarkably reduces the systemic toxicity and enhances cancer immunotherapy. Adv Mater. 2024; 36: 2309927.
  11. 11.↵
    2. Chen J,
    3. Ma F,
    4. Zhang Y,
    5. Xu M,
    6. Xu L,
    7. Liu Y, et al.
    Synergizing CXCL9 with BRD4-PROTAC using nanochaperone boosts robust T cell-dependent antitumor immune responses for cancer immunotherapy. Adv Funct Mater. 2024; 34: 2314203.
  12. 12.↵
    2. Dosta P,
    3. Dion MZ,
    4. Prado M,
    5. Hurtado P,
    6. Riojas-Javelly CJ,
    7. Cryer AM, et al.
    Matrix metalloproteinase- and pH-sensitive nanoparticle system enhances drug retention and penetration in glioblastoma. ACS Nano. 2024; 18: 14145–60.
    OpenUrlPubMed
  13. 13.↵
    2. Gao A,
    3. Chen B,
    4. Gao J,
    5. Zhou F,
    6. Saeed M,
    7. Hou B, et al.
    Sheddable prodrug vesicles combating adaptive immune resistance for improved photodynamic immunotherapy of cancer. Nano Lett. 2020; 20: 353–62.
    OpenUrlPubMed
  14. 14.↵
    2. Zhang Y,
    3. Ma S,
    4. Liu X,
    5. Xu Y,
    6. Zhao J,
    7. Si X, et al.
    Supramolecular assembled programmable nanomedicine as in situ cancer vaccine for cancer immunotherapy. Adv Mater. 2021; 33: 2007293.
  15. 15.↵
    2. Guo Y,
    3. Fan Y,
    4. Wang Z,
    5. Li G,
    6. Zhan M,
    7. Gong J, et al.
    Chemotherapy mediated by biomimetic polymeric nanoparticles potentiates enhanced tumor immunotherapy via amplification of endoplasmic reticulum stress and mitochondrial dysfunction. Adv Mater. 2022; 34: 2206861.
  16. 16.↵
    2. Ding J,
    3. Lu Y,
    4. Zhao X,
    5. Long S,
    6. Du J,
    7. Sun W, et al.
    Activating iterative revolutions of the cancer-immunity cycle in hypoxic tumors with a smart nano-regulator. Adv Mater. 2024; 36: 2400196.
  17. 17.↵
    2. Sun L,
    3. Shen F,
    4. Tian L,
    5. Tao H,
    6. Xiong Z,
    7. Xu J, et al.
    ATP-responsive smart hydrogel releasing immune adjuvant synchronized with repeated chemotherapy or radiotherapy to boost antitumor immunity. Adv Mater. 2021; 33: 2007910.
  18. 18.↵
    2. Yang H,
    3. Yang S,
    4. Guo Q,
    5. Sheng J,
    6. Mao Z.
    ATP-responsive manganese-based bacterial materials synergistically activate the cGAS-STING pathway for tumor immunotherapy. Adv Mater. 2024; 36: 2310189.
  19. 19.↵
    2. Su W,
    3. Qiu W,
    4. Li SJ,
    5. Wang S,
    6. Xie J,
    7. Yang QC, et al.
    A dual-responsive STAT3 inhibitor nanoprodrug combined with oncolytic virus elicits synergistic antitumor immune responses by igniting pyroptosis. Adv Mater. 2023; 35: 2209379.
  20. 20.↵
    2. Li Y,
    3. Cao Y,
    4. Ma K,
    5. Ma R,
    6. Zhang M,
    7. Guo Y, et al.
    A triple-responsive polymeric prodrug nanoplatform with extracellular ROS consumption and intracellular H2O2 self-generation for imaging-guided tumor chemo-ferroptosis-immunotherapy. Adv Healthcare Mater. 2024; 13: 2303568.
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section